References
- Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2016;66:7–30.
- Oberstein PE, Olive KP. Pancreatic cancer: why is it so hard to treat? Therap Adv Gastroenterol. 2013;6:321–337.
- Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321:1801–1806.
- Yeo D, He H, Baldwin GS, et al. The role of p21-activated kinases in pancreatic cancer. Pancreas. 2015;44:363–369.
- Radu M, Semenova G, Kosoff R, et al. PAK signalling during the development and progression of cancer. Nat Rev Cancer. 2014;14:13–25.
- Eswaran J, Li DQ, Shah A, et al. Molecular pathways: targeting p21-activated kinase 1 signaling in cancer–opportunities, challenges, and limitations. Clin Cancer Res. 2012;18:3743–3749.
- Jagadeeshan S, Krishnamoorthy YR, Singhal M, et al. Transcriptional regulation of fibronectin by p21-activated kinase-1 modulates pancreatic tumorigenesis. Oncogene. 2015;34:455–464.
- Haqq J, Howells LM, Garcea G, et al. Pancreatic stellate cells and pancreas cancer: current perspectives and future strategies. Eur J Cancer. 2014;50:2570–2582.
- Jagadeeshan S, Subramanian A, Tentu S, et al. P21-activated kinase 1 (Pak1) signaling influences therapeutic outcome in pancreatic cancer. Ann Oncol. 2016;27:1546–1556.
- Chow HY, Jubb AM, Koch JN, et al. p21-activated kinase 1 is required for efficient tumor formation and progression in a Ras-mediated skin cancer model. Cancer Res. 2012;72(22):5966–5975.
- Yeo D, He H, Patel O, et al. FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine. BMC Cancer. 2016;16:24.
- Ndubaku CO, Crawford JJ, Drobnick J, et al. Design of Selective PAK1 Inhibitor G-5555: improving properties by employing an unorthodox low-pK a polar moiety. ACS Med Chem Lett. 2015;6:1241–1246.
- Karpov AS, Amiri P, Bellamacina C, et al. Optimization of a dibenzodiazepine hit to a potent and selective allosteric PAK1 Inhibitor. ACS Med Chem Lett. 2015;6:776–781.
- Baker NM, Yee Chow H, Chernoff J, et al. Molecular pathways: targeting RAC-p21-activated serine-threonine kinase signaling in RAS-driven cancers. Clin Cancer Res. 2014;20:4740–4746. .
- Yeo D, He H, Phillips P, et al. Targeting PAK1 in pancreatic stellate cells increases pancreatic cancer survival. Pancreatology. 2016;16:S26–S27.
- Deacon SW, Beeser A, Fukui JA, et al. An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase. Chem Biol. 2008;15:322–331.
- Viaud J, Peterson JR. An allosteric kinase inhibitor binds the p21-activated kinase autoregulatory domain covalently. Mol Cancer Ther. 2009;8:2559–2565.
- Wong LL, Lam IP, Wong TY, et al. IPA-3 inhibits the growth of liver cancer cells by suppressing PAK1 and NF-κB activation. PLoS One. 2013;8:e68843.
- Al-Azayzih A, Missaoui WN, Cummings BS, et al. Liposome-mediated delivery of the p21 activated kinase-1 (PAK-1) inhibitor IPA-3 limits prostate tumor growth in vivo. Nanomedicine. 2016;12:1231–1239.
- Licciulli S, Maksimoska J, Zhou C, et al. FRAX597, a small molecule inhibitor of the p21-activated kinases, inhibits tumorigenesis of neurofibromatosis type 2 (NF2)-associated Schwannomas. J Biol Chem. 2013;288:29105–29114.